Cancer Vaccine Co. Files For Chapter 7
The Cambridge, Mass.-based company’s bankruptcy petition listed both its assets and debts as between $1 million and $100 million.
In June, one of Therion’s two candidates for lead product used to treat pancreatic cancer fell short in clinical tests, prompting the company to not pursue licensing of the drug with the U.S. Food and Drug...
To view the full article, register now.